|
Match
|
Document |
Document Title |
|
|
7067555 |
Sertraline oral concentrate
The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof...
|
|
|
7053122 |
Therapeutic use of aryl amino acid derivatives
The compounds of formula (I)
are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain,...
|
|
|
7053120 |
Use of carboxy compounds such as 2(4-acetoxyphenyl)2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents
The present invention relates to the use of specific carboxy compounds, more specifically to the use of 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride, in the treatment of inflammatory...
|
|
|
7049329 |
Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds...
|
|
|
7034036 |
Inhibitors of ABC drug transporters at the blood-brain barrier
The present invention relates to inhibitors of drug transporters of the ABC protein superfamily, particularly transporters present at the blood brain barrier. ABC transporter inhibitors identified...
|
|
|
7034059 |
Methods of using norfluoxetine
The invention encompasses methods of using racemic and enantiomerically pure norfluoxetine, as well as pharmaceutical compositions, pharmaceutical unit dosage forms, and kits comprising racemic and...
|
|
|
7030164 |
Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
This invention relates to a highly thermally stable novel anhydrous crystalline polymorphic form of venlafaxine hydrochloride, methods for the preparation thereof, and its use.
|
|
|
7022678 |
Pregabalin lactose conjugates
In accordance with the present invention, there is provided pregabalin lactose conjugate compounds. Also provided as part of the present invention is a novel method of central nervous system...
|
|
|
7011844 |
Formulations for the administration of fluoxetine
Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be...
|
|
|
7012071 |
Compounds for the treatment of metabolic disorders
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and...
|
|
|
7012099 |
Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments
The invention relates to the use of substituted 4-amino-1-phenylbutan-2-ol compounds in the form of their racemates, enantiomers, diastereomers or corresponding bases or corresponding salts of...
|
|
|
6984389 |
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a...
|
|
|
6960574 |
Antagonists of RF-amide neuropeptides
Disclosed are compounds having the formula:
where
R 1 =H, C 1 -C 6 alkyl, cycloalkyl,
R 2 =H, C 1 -C 6 alkyl, cycloalkyl W=C n H 2n-m —NH (n=1-6, m=0, 2, or 4),
X=
R 3 =
...
|
|
|
6960577 |
Combination therapy for treatment of refractory depression
Methods for treating a patient suffering from or susceptible to treatment resistant major depression comprising administering olanzapine and fluoxetine are disclosed.
|
|
|
6953797 |
Use of phenylheteroalkylamine derivatives
There is disclosed the use of a compound of formula (I), wherein R 1 , R 2 , X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates...
|
|
|
6949534 |
Cell adhesion inhibitors
The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical...
|
|
|
6939856 |
Method for preparing dexchlor tannate
The invention pertains to a method for preparing dexchlorpheniramine (“dexchlor”) tannate by reacting dexchlorpheniramine free base at a temperature of about 75 to about 150° C. with tannic...
|
|
|
6932985 |
Azide method and composition for controlling deleterious organisms
Disclosed is both a method and composition for controlling deleterious organisms, such as insects, nematodes and weeds by applying a compound comprised of a liquid medium comprising azide and...
|
|
|
6927223 |
Use of serotonin agents for adjunct therapy in the treatment of cancer
The invention provides a method for the treatment of cancer comprising administering a serotonin agent. Also provided is a method for the treatment of cachexia comprising administering a serotonin...
|
|
|
6924313 |
Substituted tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid trans: protein-I) and compounds, compositions...
|
|
|
6919317 |
Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator
Synergistic combinations of a squalene epoxidase inhibitor such as terbinafine and a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro, 33-desoxyascomycin are provided,...
|
|
|
6911479 |
Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (−)-venlafaxine
Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not...
|
|
|
6911217 |
Controlled release bead, a method of producing the same and multiple unit formulation comprising it
A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble...
|
|
|
6900203 |
Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
(R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to...
|
|
|
6881744 |
Carbinoxamine tannate
The invention pertains to carbinoxamine tannate and to a method for preparing carbinoxamine tannate by reacting carbinoxamine free base at a temperature of about 50 to about 150° C. with tannic...
|
|
|
6878721 |
Beta2-adrenoceptor agonists
Compounds of formula
in free or salt or solvate form, where
Ar is a group of formula
Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n,...
|
|
|
6846492 |
Use of phenylethylamine derivatives for the antimicrobial treatment of surfaces
The use of compounds of formula (1) is described, in which compounds R 1 , R 2 and R 3 are each independently of the others hydrogen; C 1 -C 20 alkyl; C 3 -C 7 cycloalkyl; C 2 -C 20 alkenyl; C 4...
|
|
|
6846837 |
Topical administration of basic antifungal compositions to treat fungal infections of the nails
Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a...
|
|
|
6841575 |
Use of 1-phenyl-3-dimethylaminopropane compounds for treatment of urinary incontinence
The invention relates to the use of 1-phenyl-3-dimethylaminopropane compounds for treating increased urinary urgency or urinary incontinence, as well as to the production of corresponding medicaments.
|
|
|
6809090 |
Derivatives of N-(iminomethy)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them
N-(imino)amines and their preparation and their use as NO synthase inhibitors and selective or non-selective traps for a reactive oxygen species.
|
|
|
6770636 |
Phenyl-and phenylalkyl-substituted ethanolamines and ethylenediamines
Compounds of formula 1, wherein: R 1 is hydrogen, hydroxy, CF 3 , NO 2 , CN, halogen, C 1 -C 8 -alkyl, or C 1 -C 8 -alkoxy; R 2 , R 3 , and R 4 independently of one another are hydrogen, C 1...
|
|
|
6765022 |
Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
Described are cyclobexylamine derivatives of Formula I, Formula II, or Formula III and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel...
|
|
|
6765023 |
Use of substituted N, N-disubstituted reverse aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer...
|
|
|
6730706 |
Treatments using venlafaxine
This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit...
|
|
|
6730329 |
Zinc containing compositions for anti-viral use
One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one...
|
|
|
6727283 |
Sertraline oral concentrate
The present invention provides an essentially nonaqueous, liquid pharmaceutical concentrate composition for oral administration containing sertraline or a pharmaceutically acceptable salt thereof...
|
|
|
6723752 |
(R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1 )-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma...
|
|
|
6723749 |
Fatty acid synthase inhibitors
This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
|
|
|
6723753 |
Substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer...
|
|
|
6683114 |
Treatment of psoriasis
Norepinephrine reuptake inhibitors are used to treat psoriasis.
|
|
|
6683099 |
Substituted N,N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer...
|
|
|
6683113 |
(R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma...
|
|
|
6680319 |
Isoxazolecarboxamide derivatives
The invention relates to novel N-(substituted phenyl)-N′-[ω-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The...
|
|
|
6677380 |
Substituted N, N-disubstituted mercapto amino compounds useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer...
|
|
|
6677379 |
Substituted N,N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted polycyclic aryl and heteroary tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer...
|
|
|
6677375 |
Substituted N,N-bis-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer...
|
|
|
6649614 |
Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent for treatment of depression or anxiety
The present invention relates to the treatment of depression and/or anxiety by the administration of a combination of a specific class of NK-1 receptor antagonists and an antidepressant or...
|
|
|
6632842 |
Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease...
|
|
|
6624200 |
Bioadhesive progressive hydration tablets
A bioadhesive composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by...
|
|
|
6620852 |
Topical anesthetic
The present invention is directed to an improved flowable anesthetic composition that does not need to be applied by an applicator. The anesthetic composition of the present invention may be...
|